Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00252850 | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease | PHASE1 | COMPLETED | 12 | — | — | Jun 1, 2005 | Mar 1, 2007 | Nov 10, 2022 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| CERE-120: AAV2-NTN | GENETIC | - |
Inclusion Criteria: * Diagnosis of bilateral idiopathic Parkinson's Disease of at least 5 years duration since diagnosis with motor fluctuations, despite adequate oral antiparkinsonian therapy. * Diagnosis of moderate to severe Parkinson's Disease based on clinical rating scales. * Males or nonpreg...